These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The outcomes of aflibercept therapy in patients with age-related macular degeneration resistant to bevacizumab or ranibizumab. Unsal E; Cubuk MO J Curr Ophthalmol; 2018 Dec; 30(4):337-342. PubMed ID: 30555967 [TBL] [Abstract][Full Text] [Related]
3. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration. Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583 [TBL] [Abstract][Full Text] [Related]
6. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
7. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months. Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046 [TBL] [Abstract][Full Text] [Related]
8. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION. Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146 [TBL] [Abstract][Full Text] [Related]
9. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration. Abu Dail Y; Seitz B; Sideroudi H; Abdin AD Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883 [TBL] [Abstract][Full Text] [Related]
10. Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Grewal DS; Gill MK; Sarezky D; Lyon AT; Mirza RG Eye (Lond); 2014 Jul; 28(7):895-9. PubMed ID: 24833178 [TBL] [Abstract][Full Text] [Related]
11. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
13. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Chan CK; Jain A; Sadda S; Varshney N Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034 [TBL] [Abstract][Full Text] [Related]
14. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration. Inan S; Polat O; Karadas M; Inan UU Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625 [No Abstract] [Full Text] [Related]
15. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684 [TBL] [Abstract][Full Text] [Related]
16. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Cho H; Shah CP; Weber M; Heier JS Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432 [TBL] [Abstract][Full Text] [Related]
17. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Moon DRC; Lee DK; Kim SH; You YS; Kwon OW Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506 [TBL] [Abstract][Full Text] [Related]
18. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients. Hall LB; Zebardast N; Huang JJ; Adelman RA J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305 [TBL] [Abstract][Full Text] [Related]
19. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy. Ricci F; Parravano M; Regine F; Sciamanna M; Tedeschi M; Missiroli F; Varano M Eye (Lond); 2016 Aug; 30(8):1077-83. PubMed ID: 27229701 [TBL] [Abstract][Full Text] [Related]
20. Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration. Wang Z; Li M; Yao Y; Hu J; Tang J; Tang R; Piao Z; Qu J J Ophthalmol; 2020; 2020():9340356. PubMed ID: 33005448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]